Characteristics | All patients (n = 96) | Refractory AML (n = 37) | Relapsed AML after chemotherapy (n = 16) | Relapsed AML after allo-HSCT (n = 43) | P |
---|---|---|---|---|---|
Age, median (IQR), y | 45 (33–55) | 48 (38–57) | 45.5 (33–64) | 41 (32–52) |  |
Gender, No (%) | 0.47 | ||||
 Male | 51 (53.1) | 21 (56.8) | 10 (62.5) | 20 (46.5) |  |
 Female | 45 (46.9) | 16 (43.2) | 6 (37.5) | 23 (53.5) |  |
Prior hypomethylating agent†, No (%) | 0.06 | ||||
 Yes | 36 (37.5) | 9 (24.3) | 9 (56.3) | 18 (41.9) |  |
 No | 60 (62.5) | 28 (75.7) | 7 (43.8) | 25 (58.1) |  |
Cytogenetics‡, No (%) | 0.55 | ||||
 Favorable | 6 (6.3) | 4 (10.8) | 0 (0) | 2 (4.7) |  |
 Intermediate | 53 (55.2) | 18 (48.7) | 10 (62.5) | 25 (58.1) |  |
 Poor | 27 (28.1) | 12 (32.4) | 3 (18.8) | 12 (27.9) |  |
 Unknown | 10 (10.4) | 3 (8.1) | 3 (18.8) | 4 (9.3) |  |
ELN classification, No (%) | 0.68 | ||||
 Favorable | 17 (17.7) | 7 (18.9) | 2 (12.5) | 8 (18.6) |  |
 Intermediate | 22 (22.9) | 10 (27.0) | 5 (31.3) | 7 (16.3) |  |
 Adverse | 57 (59.4) | 20 (54.1) | 9 (56.3) | 28 (65.1) |  |
Number of VEN cycles, No (%) | 0.01 | ||||
 One | 45 (46.9) | 25 (67.6) | 6 (37.5) | 14 (32.6) |  |
 Two | 42 (43.7) | 12 (32.4) | 8 (50.0) | 22 (51.2) |  |
 Three | 9 (9.4) | 0 (0) | 2 (12.5) | 7 (16.3) |  |
 Patients bridge to Allo-HSCT, No (%) | 40 (41.7) | 26 (70.3) | 7 (43.8) | 7 (16.3) |  < 0.01 |
Molecular abnormalities, No (%) | |||||
 NPM1 | 11 (11.5) | 3 (8.1) | 2 (12.5) | 6 (14.0) | 0.71 |
 AML1-ETO | 6 (6.3) | 4 (10.8) | 0 (0) | 2 (4.7) | 0.28 |
 CEBPA | 10 (10.4) | 3 (8.1) | 2 (12.5) | 5 (11.6) | 0.84 |
 TET2 | 41 (42.7) | 13 (35.1) | 7 (43.8) | 21 (48.8) | 0.46 |
 DNMT3A | 18 (18.8) | 9 (24.3) | 2 (12.5) | 7 (16.3) | 0.51 |
 IDH1/2 | 14 (14.6) | 8 (21.6) | 3 (18.8) | 3 (7.0) | 0.16 |
 FLT3 | 19 (19.8) | 7 (18.9) | 2 (12.5) | 10 (23.3) | 0.64 |
 ASXL1 | 22 (22.9) | 7 (18.9) | 4 (25.0) | 11 (25.6) | 0.76 |
 RUNX1 | 22 (22.9) | 6 (16.2) | 3 (18.8) | 13 (30.2) | 0.30 |
 TP53 | 7 (7.3) | 4 (10.8) | 0 (0) | 3 (7.0) | 0.38 |
 MLL | 7 (7.3) | 2 (5.4) | 3 (18.8) | 2 (4.7) | 0.15 |
 EZH2 | 6 (6.3) | 1 (2.7) | 1 (6.3) | 4 (9.3) | 0.48 |
 BCL6 | 7 (7.3) | 1 (2.7) | 1 (6.3) | 5 (11.6) | 0.31 |
 BCOR | 7 (7.3) | 6 (16.2) | 0 (0) | 1 (2.3) | 0.03 |
 GATA2 | 5 (5.2) | 1 (2.7) | 0 (0) | 4 (9.3) | 0.25 |
 RAS | 9 (9.4) | 6 (16.2) | 1 (6.3) | 2 (4.7) | 0.19 |
 CD101 | 8 (8.3) | 2 (5.4) | 1 (6.3) | 5 (11.6) | 0.57 |